Why maalox recalled

Contact the company for a copy of any references, attachments or enclosures. Notice about Health Canada advisories. Subject: Maalox Multi Action bismuth subsalicylate and confusion with other Maalox liquid products.

Novartis Consumer Health Canada Inc. It is important to know that Maalox Multi Action and other Maalox liquid products have similar names, labels and packaging, but contain very different ingredients. The unintentional use of bismuth subsalicylate by some people taking certain medicines or who have certain health conditions, could cause serious side effects.

For example, people taking medicine for thinning the blood have an increased risk of bleeding if taking Maalox Multi Action. There have been Canadian reports of serious adverse events that have been reported in patients using Maalox Multi Action instead of other Maalox liquid products.

Maalox Multi Action and other Maalox liquid products have similar names, labels and packaging, which if confused, have the potential to cause serious side effects. Maalox Multi Action and other Maalox liquid products contain different ingredients and are not interchangeable.

Amneal Pharmaceuticals of New York is recalling three lots of nizatidine oral solution due to potential contamination with N-Nitrosodimethylamine NDMA , a probable human carcinogen. The lots were distributed by Gemini Laboratories, a subsidiary of Amneal Pharmaceuticals. Amneal Pharmaceuticals initiated the voluntary recall April 15, The FDA designated the recall Class II on April 24, , signaling use of the product could cause temporary or medically reversible adverse health consequences.

A remote possibility of serious harm also exists. Nizatidine is a prescription medication used for the short-term treatment and maintenance therapy of ulcers and for the treatment of esophagitis and associated heartburn due to gastroesophageal reflux disease, or GERD. Sign in. Annals of Long-Term Care. First Report Managed Care. Integrated Healthcare Executive. Pharmacy Learning Network. Veterans Health Today. For Advertisers. Editorial Description. Publishing Staff. Expert Insights.

Interactive Features. AMCP Nexus Talking Therapeutics. Drug Recalls. Infectious Diseases. Medication Safety. Opioid Use Disorder. Copied to clipboard. Submit Feedback. Email Address. Class I Recall for Antibiotic Injection. A prescription antibiotic injection was placed under a class I recall after a customer found glass particles in a vial. Methocarbamol tablets are under a class I recall due to a labeling error listing incorrect medication strength.

Cholesterol Drug Recalled. A class II recall was issued for prescription tablets used to treat high cholesterol and triglyceride levels. When ranitidine reacts, it produces harmful levels of NDMA and becomes a potential health risk for consumers. If present in high enough concentrations, the compound could cause cancer.

Consumers of antacids that contain ranitidine, such as Zantac and ranitidine, who developed cancer could be entitled to compensation. Ranitidine-based drugs, available in prescription and over-the-counter variants, serve as medications for heartburn, ulcers of the stomach and intestines, acid reflux, and other related health conditions.

Innumerable prescriptions and other over-the-counter OTC purchases occurred for consumers wishing to treat problems arising from the acid produced in the stomach.

After tests have found ranitidine to be harmful to people, and the potential cause of certain cancers, the following antacids have been recalled by the FDA:. Current advice from the FDA for daily users of OTC antacids containing ranitidine is to stop using them and to dispose of them safely, in line with FDA drug disposal guidelines. Patients prescribed ranitidine are prompted to discuss alternative treatment options with their chosen healthcare professional or doctor.

Pregnant mothers are also advised to discontinue using the treatments since unborn babies can suffer exposure to NDMA in the womb, according to Placenta , a medical journal.